Rochelle Bagatell, MD

Dr. Rochelle Bagatell is a pediatric oncologist with expertise in the care of children with solid tumors, particularly neuroblastoma and sarcomas.

Areas of Expertise: Developmental therapeutics, Neuroblastoma, Sarcoma therapy
Appointments and Referrals: 1-800-TRY-CHOP (1-800-879-2467)

  • Background

    Rochelle Bagatell, MD, is a pediatric oncologist with expertise in the care of children with solid tumors. She has a particular interest in the treatment of patients with sarcomas and neuroblastoma, and co-directs the solid tumor program at The Children's Hospital of Philadelphia.

    Current treatment regimens are effective for many children diagnosed with solid tumors in childhood, and the collaborative approach taken at Children's Hospital allows patients to benefit from the expertise of surgeons, pathologists, radiologists, radiation oncologists, nurses, nutritionists and other specialists who work together to provide state-of-the-art care for patients. The solid tumor team is committed to optimizing the effectiveness of current therapies while trying to minimize the side effects of treatment.

    This group is also committed to developing new treatments for childhood solid tumors. As a member of Children's Hospital’s oncology developmental therapeutics team, Dr. Bagatell is involved in research studies (clinical trials) of new agents for patients whose cancers don't respond to initial or established treatments. She and colleagues conduct research trials that provide patients access to the newest anticancer medications. The team studies novel treatments that haven't previously been administered to children. These trials permit better understanding of how to use new treatments in the most effective way. The team is currently expanding the number of new agent trials available to patients, and collaborates with colleagues from around the region and nation in efforts to advance the field.

    While there are tremendous challenges inherent in the pursuit of new treatments, the solid tumor and developmental therapeutics teams have the opportunity to build upon the expertise at Children’s Hospital to develop newer, less toxic treatments for childhood cancer. Dr. Bagatell’s highest priority is to make innovative treatments available to the children who need them.

  • Education and Training

    Medical School

    MD - University of Arizona, Tucson, AZ


    Pediatrics - University of Arizona, Tucson, AZ


    Pediatrics - University of Arizona, Tucson, AZ


    Pediatric Hematology/Oncology - Children's Memorial Hospital, Northwestern University, Chicago, IL
    Pediatric Hematology/Oncology - University of Arizona, Tucson, AZ

    Board Certification


  • Titles and Academic Titles

    Attending Physician

    Solid Tumor Section Chief

    Associate Professor, Perelman School of Medicine at the University of Pennsylvania

  • Departments and Services
  • Research Interests

    Clinical trials

  • Publications




    Parikh S, Bagatell R. Bone tumors. In: Florin TA, Ludwig S, editors. Netter's pediatrics. Philadelphia: Saunders Elsevier; 2011. Ch. 60, p. 366-71.

    Bagatell R, Park J. Neuroblastoma. In: Lanzkowsky P, editor. Handbook of pediatric hematology and oncology. 5th ed. London, UK: Academic Press; 2011. Ch. 22, p. 671.


    Adamson P, Bagatell R, Balis FM, Blaney SM. In: Pizzo PA, Adamson PC, Poplack DG (eds). Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins. 2010.



    Johnson K, Aplenc R, Bagatell R. Survival by race among children with extracranial solid tumors in the United States 1985-2005 [abstract]. American Society for Clinical Oncology (ASCO); 2010 Jun; Chicago, IL.


    Fox E, Aplenc R, Widemann BC, Chuk MK, Bagatell R, Kim A, et al. Phase I trial and pharmacokinetic study of cediranib in children with recurrent or refractory solid tumors. AACR/EORT Molecular Targets Meeting; 2009 Nov; Boston, MA.

    Bagatell R, Herzog CE, Trippett TM, Winter E, Dall GC, Grippo JF, et al. Pharmacokinetically guided phase I trial of the IGF-1 antagonist RG1507 administered weekly. AACR/EORTC Molecular Targets Meeting; 2009 Nov; Boston, MA.

    Bagatell R, Wagner LM, Cohn SL, Maris JM, Reynolds CP, Stewart CF, et al. Irinotecan + temozolomide in children with recurrent or refractory neuroblastoma: a phase II Children's Oncology Group study, American Society for Clinical Oncology (ASCO); 2009 Jun; Orlando, FL.



    Bagatell R, Herzog CE, Trippett TM, Grippo JF, Cirrincione-Dall G, Fox E, et al. Pharmacokinetically guided phase I trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res. 2011 Feb 1;17(3):611-9. Epub 2010 Dec 2. Cited in PubMed: PMID 21127194. Read the abstract

    Bagatell R, London WB, Wagner LM, Voss SD, Stewart CF, Maris JM, et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Jan 10;29(2):208-13. Epub 2010 Nov 29. Cited in PubMed: PMID 21115869. Read the abstract

    Johnson KA, Aplenc R, Bagatell R. Survival by race among children with extracranial solid tumors in the United States between 1985 and 2005. Pediatr Blood Cancer. 2011 Mar;56(3):425-31. Cited in PubMed: PMID 21072824. Read the abstract


    Trippett TM, Herzog C, Whitlock JA, Wolff J, Juttesch J, Bagatell R, et al. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigator's consortium. J Clin Oncol. 2009 Oct 20:27(30):5102-8. Epub 2009 Sep 21. Cited in PubMed: PMID 19770383. Read the abstract

    Bagatell R, Beck-Popovic M, London WB, Zhang Y, Pearson AD, Matthay KK, et al. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol. 2009 Jan 20;27(3):365-70. Epub 2008 Dec 1. Cited in PubMed: PMID 19047282. Read the article

    Posters and Presentations


    Bagatell R. Clinical trials and experimental therapies [invited lecture]. Childhood Cancer Symposium, Alex's Lemonade Stand Foundation; 2010 Jun 26; Philadelphia, PA.


    Bagatell R. New endpoint and trial design to define the dose of a molecularly targeted anti-cancer agent in children [invited lecture]. Children's Cancer Research Center Seminar, The Children's Hospital of Philadelphia; 2009 Sep 8; Philadelphia, PA.

    Bagatell R. How to read the medical literature [invited lecture]. Children's Neuroblastoma Cancer Foundation Conference; 2009 Jul 18; Chicago, IL.

  • Editorial and Academic Positions

    Editorial positions

    Editorial Board, The Oncologist

    Ad Hoc Reviewer:

    • Journal of Clinical Oncology
    • Lancet Oncology
    • Cancer Research
    • Clinical Cancer Research
    • Cancer Chemotherapy and Pharmacology
    • Pediatric Blood and Cancer
    • Molecular Cancer Therapeutics

    Academic positions

    The Children's Hospital of Philadelphia:

    • 2009-present, Co-leader, Clinical Restructuring Team
    • 2010-present, Director, Solid Tumor Service, Division of Oncology
    • 2009, Judge, CHOP Research Poster Day
    • 2009-present, Oncology Website Redesign Committee
    • 2009-present, SPECT CT Committee, Department of Radiology
    • 2009-present, Clinical Research Quality Assurance Committee, Division of Oncology
    • 2008-present, Pediatric Protocol Review Committee, Division of Oncology